Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis
Status:
Completed
Trial end date:
2019-10-21
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2 study
evaluating the safety and tolerability of NCX 4251 (fluticasone propionate nanocrystal)
Ophthalmic Suspension 0.1% QD and BID for the treatment of acute exacerbations of
blepharitis. The study will be performed in two sequential dose escalating cohorts.
The study is designed to select the dose(s) of NCX 4251 to advance into the next stage of
development, and to assess the safety and tolerability of NCX 4251 Ophthalmic Suspension.